Warsaw, IN, January 28, 2014 – Early results of the limited commercial release of the Re+Line Bunion Correction System were presented during the New York Podiatric Clinical Conference (NYSPMA) held in New York on January 24-26.
Lon S. Weiner, M.D., Chief of Orthopaedic Trauma at Lenox Hill Hospital in New York, presented early clinical results of several of his patients. Dr. Weiner commented, “ The preliminary results with Re+Line are very encouraging. By achieving superior stability, we have observed faster healing, earlier weight bearing and less post-operative pain than with other techniques and implants”. We look forward to further tracking of these positive early patient outcomes”.
The new Re+Line system has obtained FDA clearance and CE mark certification is pending. Re+Line complements the company’s flagship product, the Nextra Hammertoe Correction System. Nextremity Solutions estimates that over 400,000 bunion surgeries were performed in the US in 2013 and that 30-40% of bunion operations are performed together with hammertoe surgery.
Leerink Swann, a leading investment bank, estimates the US bunion surgery market is valued at $240 million. The bunion segment is fragmented with over 130 different techniques reported in the literature. The Re+Line system is designed to provide surgeons with a convenient, single-use kit which combines the Re+Line Bunion Correction Plate with the necessary instruments for a precise bunionectomy with stable fixation and uniform compression.